Publications

Gayvert KM, Aly O, Platt J, Bosenberg MW, Stern DF, Elemento O.  2017.  A Computational Approach for Identifying Synergistic Drug Combinations.. PLoS Comput Biol. 13(1):e1005308.

Vikova V, Jourdan M, Robert N, Requirand G, Boireau S, Bruyer A, Vincent L, Cartron G, Klein B, Elemento O et al..  2019.  Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.. Theranostics. 9(2):540-553.

Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR.  2012.  Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons.. Cell. 149(7):1635-46.

Nauseef JT, Chu TR, Hooper WF, Alonso A, Oku A, Geiger H, Goldstein ZR, Shah M, Sigouros M, Manohar J et al..  2025.  A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer.. NPJ Precis Oncol. 9(1):91.

Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, Tagawa ST, Nanus DM, Molina AM, Beltran H et al..  2020.  Common germline-somatic variant interactions in advanced urothelial cancer.. Nat Commun. 11(1):6195.

Shah SB, Carlson CR, Lai K, Zhong Z, Marsico G, Lee KM, Vélez NEFélix, Abeles EB, Allam M, Hu T et al..  2023.  Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas.. Nat Mater. 22(4):511-523.

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang SN, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL et al..  2016.  Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.. Blood. 127(7):858-68.

Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M et al..  2022.  Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.. JCI Insight. 7(4)

Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JMiguel, Robinson B, Elemento O et al..  2016.  Clonal evolution of chemotherapy-resistant urothelial carcinoma.. Nat Genet. 48(12):1490-1499.

Rosenquist R, Cuppen E, Buettner R, Caldas C, Dreau H, Elemento O, Frederix G, Grimmond S, Haferlach T, Jobanputra V et al..  2022.  Clinical utility of whole-genome sequencing in precision oncology.. Semin Cancer Biol. 84:32-39.

Jobanputra V, Wrzeszczynski KO, Buttner R, Caldas C, Cuppen E, Grimmond S, Haferlach T, Mullighan C, Schuh A, Elemento O.  2022.  Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology.. Semin Cancer Biol. 84:23-31.

Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JMiguel, Elemento O et al..  2019.  Clinical features of neuroendocrine prostate cancer.. Eur J Cancer. 121:7-18.

Kolin DA, Kulm S, Elemento O.  2020.  Clinical and Genetic Characteristics of Covid-19 Patients from UK Biobank.. medRxiv.

Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GMarco, Orlando F, Fedrizzi T, Ku S-Y, Dann E et al..  2020.  Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.. J Clin Invest. 130(4):1653-1668.

Hwang I, Pan H, Yao J, Elemento O, Zheng H, Paik J.  2020.  CIC is a critical regulator of neuronal differentiation.. JCI Insight. 5(9)

Bakhoum SF, Ngo B, Laughney AM, Cavallo J-A, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK et al..  2018.  Chromosomal instability drives metastasis through a cytosolic DNA response.. Nature. 553(7689):467-472.

Ceballos-Chávez M, Subtil-Rodríguez A, Giannopoulou EG, Soronellas D, Vázquez-Chávez E, Vicent GP, Elemento O, Beato M, Reyes JC.  2015.  The chromatin Remodeler CHD8 is required for activation of progesterone receptor-dependent enhancers.. PLoS Genet. 11(4):e1005174.

Li W, Xia S, Aronova A, Min IM, Verma A, Scognamiglio T, Gray KD, Ullmann TM, Liang H, Moore MD et al..  2018.  CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules.. J Surg Oncol. 118(6):1042-1049.

Bruno NE, Nwachukwu JC, Srinivasan S, Nettles CC, Izard T, Jin Z, Nowak J, Cameron MD, Boregowda SV, Phinney DG et al..  2021.  Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling.. Nat Chem Biol. 17(3):307-316.

Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y et al..  2019.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.. Cancer Cell. 35(5):817-819.

Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y et al..  2019.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.. Cancer Cell. 35(4):603-617.e8.

Kulm S, Kolin DA, Langhans MT, Kaidi AC, Elemento O, Bostrom MP, Shen TS.  2022.  Characterization of Genetic Risk of End-Stage Knee Osteoarthritis Treated with Total Knee Arthroplasty: A Genome-Wide Association Study.. J Bone Joint Surg Am. 104(20):1814-1820.

Napoli S, Cascione L, Rinaldi A, Spriano F, Guidetti F, Zhang F, Cacciapuoti MTeresa, Mensah AAdjeiwaa, Sartori G, Munz N et al..  2022.  Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma.. Haematologica. 107(5):1131-1143.

Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S et al..  2014.  Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.. Cancer Discov. 4(9):1022-35.

Guo C, Crespo M, Gurel B, Dolling D, Rekowski J, Sharp A, Petremolo A, Sumanasuriya S, Rodrigues DN, Ferreira A et al..  2021.  CD38 in Advanced Prostate Cancers.. Eur Urol. 79(6):736-746.